Jared Moskowitz is having a complicated spring. The Florida Democrat is drawing fire from the Democratic Socialists of America, who are backing a primary challenger in a district that already leans Republican, and social media spent the week debating whether he deserves solidarity or a pink slip from the base. While that argument ran its course on Bluesky, Moskowitz filed two stock disclosures on the same day: a sale out of a pharmaceutical distributor and a buy into a biotech. Whether you read that as portfolio rebalancing or something more interesting probably depends on how charitable you're feeling toward the member class in general.
The Political Backdrop
The online chatter around Moskowitz this week breaks into two camps. One side is furious that a socialist challenger named Oliver Larkin is mounting a primary against him in what's already a Republican-leaning South Florida seat, treating the whole thing as a gift-wrapped pickup opportunity for the GOP. The other side thinks the DSA is making a principled stand and donors should back off. One post specifically compared Moskowitz's conduct to Donald Trump's, which tells you roughly where that camp lands on the nuance spectrum.
What's not in dispute: Moskowitz is a high-visibility Democrat in a district where the margin for error is thin. He's loud, he's on television a lot, and he has opinions. That profile means the trades he files get read.
May 6: One Sale, One Buy, One Filing
Per his disclosure record on Blind Trust, Moskowitz reported two trades on May 6, 2026, both in the $1,001 to $15,000 range.
He sold Cencora (COR). He bought Gilead Sciences (GILD).
Cencora is one of the three giant pharmaceutical distributors that sit between drug manufacturers and the pharmacies and hospitals that actually dispense medications. It's a logistics and distribution play, not a drug developer. Gilead Sciences makes drugs. Antivirals, oncology treatments, HIV therapies. The two companies touch the same industry but occupy completely different positions in it.
Rotating out of a distributor and into a manufacturer on the same day is a directional call about where you think value is moving inside healthcare. It's not a random pairing. Someone decided that Cencora had run its course and that Gilead had more road ahead of it. That someone was Jared Moskowitz, or his financial advisor, or both.
Moskowitz sits on the House Committee on Foreign Affairs and the House Committee on the Judiciary. Neither of those has jurisdiction over pharmaceutical pricing, drug approval, or healthcare reimbursement policy. So there's no committee-level conflict angle to work here. The trades live entirely outside his oversight remit. They're just trades.
His Full Trading Record: Honest Accounting
Moskowitz has 59 scored trades in the Blind Trust database. Thirty-three came out positive against the S&P 500 over a 30-day window. Twenty-six did not. The mean 30-day alpha across all scored trades is 0.2 percent. That's roughly flat. Not a genius, not a disaster.
The headline-grabbing end of his record is the AVGO buy he filed on March 31, 2026, which posted 21.7 percent alpha in 30 days. That one carries a committee-overlap flag: Broadcom (AVGO) lands in the Technology bucket, and Moskowitz does have committee exposure that touches technology-adjacent oversight. The Judiciary subcommittee on Crime and Federal Government Surveillance gets into the neighborhood. Whether that overlap is meaningful or coincidental is a question the data can't answer for you.
He also bought American Express (AXP) twice on October 10, 2025, in two separate size buckets ($1,001 to $15,000 and $15,000 to $50,000). Both came back with 13.8 percent alpha at 30 days. American Express lands in the Financial Services overlap category. Moskowitz is not on the House Financial Services Committee. The committee-overlap designation here appears to reflect the sector classification, not a direct jurisdictional match. Worth noting the distinction.
The other end of the ledger deserves equal airtime. He sold Tractor Supply (TSCO) in two tranches on March 23, 2026, and both came back negative 10.0 percent alpha. He also sold Automatic Data Processing (ADP) the same day, which posted negative 11.6 percent. Three sales in one session, all pointing the wrong direction. No committee overlap on any of them, so there's no oversight angle. They were just bad timing, or a bad read, or the kind of thing that happens when you're running a portfolio while also running for your political life.
Thirty-three wins, twenty-six losses, mean alpha barely above zero. File it honestly: that's a coin flip with a slight edge, not a stat line that demands a congressional hearing.
The Votes He's Been Casting
While the portfolio has been relatively quiet, Moskowitz has been active on the floor. He voted Yea on the TRIA Program Reauthorization Act of 2026 on June 29, which extends the federal terrorism risk insurance backstop. That one matters to insurers and commercial real estate, not to pharmaceutical distributors or biotech firms. It's a floor vote well outside his committee lanes, which means it's just a vote.
He also voted Yea on the Financial Exploitation Prevention Act of 2025 on June 25, which covers financial fraud targeting vulnerable adults. Again, outside his committees. He voted Yea on the 21st Century ROAD to Housing Act on June 23. He voted Nay on FISA extension on June 11, which is actually inside his Judiciary committee territory, specifically the subcommittee on Crime and Federal Government Surveillance. His Nay put him on the losing side of a failed bill, which at least shows the subcommittee's work wasn't entirely academic.
None of these votes produced a flagged trade-timing overlap in the data. The vote-trade overlap table is empty for Moskowitz's recent 90-day window. The May 6 trades preceded most of these votes by weeks. The calendar doesn't produce a suspicious pairing here.
The Challenger Problem
The primary threat from Oliver Larkin and the DSA is a different kind of accountability question than the brokerage filings, but they're not entirely unrelated atmospherically. A member getting challenged from the left tends to have their full record scrutinized harder. Donors and voters who are already skeptical will look at the disclosure filings and the vote history together, even when the data doesn't connect them.
What Moskowitz's record actually shows is a Democratic member of Congress, serving on Foreign Affairs and Judiciary, who trades stocks in sectors his committees don't touch, posts aggregate alpha barely above zero across 59 trades, and filed a healthcare sector rotation on the same day in May. His most eyebrow-adjacent trades, the AVGO and AXP buys, are months old and don't sit near any recent votes.
The DSA's beef with him appears to be ideological, not financial. The trading record, read honestly, doesn't hand them much ammunition. A 33-for-59 record at 0.2 percent mean alpha is not the portfolio of someone who's figured something out.
What the Filings Don't Say
Members are required to disclose. They're not required to divest, recuse, abstain, or explain themselves. Moskowitz's healthcare rotation on May 6 is in the public record because the law says it has to be. What the law doesn't require is any accounting of why Cencora was wrong and Gilead was right, or whether the decision had anything to do with the legislative calendar, or whether it was his advisor's call entirely.
The disclosure regime gives you the what and the when. Everything else is yours to interpret.
The receipts are public. Make of them what you make of them.